Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients.

Huang SP, Lin VC, Lee YC, Yu CC, Huang CY, Chang TY, Lee HZ, Juang SH, Lu TL, Bao BY.

Eur J Cancer. 2013 Nov;49(17):3729-37. doi: 10.1016/j.ejca.2013.07.012. Epub 2013 Aug 3.

PMID:
23920401
2.

Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.

Huang CN, Huang SP, Pao JB, Hour TC, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, Wu PP, Huang CY, Hsieh CJ, Bao BY.

J Intern Med. 2012 May;271(5):499-509. doi: 10.1111/j.1365-2796.2011.02449.x. Epub 2011 Sep 29.

3.

Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.

Huang CN, Huang SP, Pao JB, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, Wu PP, Pu YS, Hsieh CJ, Bao BY.

Ann Oncol. 2012 Mar;23(3):707-13. doi: 10.1093/annonc/mdr264. Epub 2011 Jun 6.

PMID:
21652578
4.

Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.

Lin VC, Huang CY, Lee YC, Yu CC, Chang TY, Lu TL, Huang SP, Bao BY.

Arch Toxicol. 2014 Apr;88(4):901-11. doi: 10.1007/s00204-014-1196-8. Epub 2014 Jan 22.

PMID:
24448834
5.

Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy.

Huang SP, Bao BY, Hour TC, Huang CY, Yu CC, Liu CC, Lee YC, Huang CN, Pao JB, Huang CH.

PLoS One. 2012;7(7):e41219. doi: 10.1371/journal.pone.0041219. Epub 2012 Jul 23.

6.

Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy.

Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, Lan YH, Lu TL, Lee HZ, Chen LM, Ting WC, Hsieh CJ, Huang SP.

Int J Cancer. 2012 Feb 15;130(4):876-84. doi: 10.1002/ijc.26091. Epub 2011 May 25.

7.

Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.

Fradet V, Lessard L, Bégin LR, Karakiewicz P, Masson AM, Saad F.

Clin Cancer Res. 2004 Dec 15;10(24):8460-4.

8.

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.

Gannon PO, Lessard L, Stevens LM, Forest V, Bégin LR, Minner S, Tennstedt P, Schlomm T, Mes-Masson AM, Saad F.

Eur J Cancer. 2013 Jul;49(10):2441-8. doi: 10.1016/j.ejca.2013.02.026. Epub 2013 Mar 28.

PMID:
23541563
9.

Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence.

Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Stringer B.

Clin Cancer Res. 2004 Apr 1;10(7):2466-72.

10.

CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.

Voutsadakis IA, Vlachostergios PJ, Daliani DD, Karasavvidou F, Kakkas G, Moutzouris G, Melekos MD, Papandreou CN.

Urol Int. 2012;88(2):158-64. doi: 10.1159/000335299. Epub 2012 Jan 28.

PMID:
22286396
11.

Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.

Huang SP, Bao BY, Wu MT, Choueiri TK, Goggins WB, Liu CC, Huang CY, Pu YS, Yu CC, Wu TT, Huang CN, Huang CH, Wu WJ.

Aging Male. 2012 Mar;15(1):34-41. doi: 10.3109/13685538.2011.580398. Epub 2011 May 26.

PMID:
21615239
12.

Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Shui IM, Lindström S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Le Marchand L, Ma J, Navarro C, Overvad K, Schumacher FR, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, Mucci LA, Yeager M, Giovannucci E, Kraft P.

Eur Urol. 2014 Jun;65(6):1069-75. doi: 10.1016/j.eururo.2013.12.058. Epub 2014 Jan 4.

14.

The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ.

Cancer Res. 2008 Aug 15;68(16):6762-9. doi: 10.1158/0008-5472.CAN-08-0107.

15.

Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases.

Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM, Saad F.

Clin Cancer Res. 2006 Oct 1;12(19):5741-5.

16.

Impact of surgical margin status on prostate-cancer-specific mortality.

Chalfin HJ, Dinizo M, Trock BJ, Feng Z, Partin AW, Walsh PC, Humphreys E, Han M.

BJU Int. 2012 Dec;110(11):1684-9. doi: 10.1111/j.1464-410X.2012.11371.x. Epub 2012 Jul 12.

17.

Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.

Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, Yang XJ, Kozlowski J, Smith N, Kundu SD, Yang G, Raji AA, Javonovic B, Pins M, Lindholm P, Guo Y, Catalona WJ, Lee C.

Clin Cancer Res. 2009 May 15;15(10):3557-67. doi: 10.1158/1078-0432.CCR-08-1656. Epub 2009 May 15.

18.

Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study.

Lessard L, Bégin LR, Gleave ME, Mes-Masson AM, Saad F.

Br J Cancer. 2005 Oct 31;93(9):1019-23.

19.

Transcriptional activation of the human prostatic acid phosphatase gene by NF-kappaB via a novel hexanucleotide-binding site.

Zelivianski S, Glowacki R, Lin MF.

Nucleic Acids Res. 2004 Jul 7;32(12):3566-80. Print 2004.

20.

Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer.

Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY.

Int J Cancer. 2014 Dec 1;135(11):2661-7. doi: 10.1002/ijc.28904. Epub 2014 Apr 22.

Supplemental Content

Support Center